CA
JAZZ icon

Calton & Associates’s Jazz Pharmaceuticals JAZZ Stock Holding History

Calton & Associates’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-390
Closed -$59K – 831
2017
Q4 		$59K Buy
+390
New +$54.1K 0.01% 642

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
SIG
Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Calton & Associates's JAZZ Position: Q1 2018 in Review

Calton & Associates sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2018, closing a stake of 390 shares — an estimated $59K sold.

Calton & Associates first reported a position in JAZZ in Q4 2017 and held it in 1 quarter. The position peaked at $59K in Q4 2017. 323 funds tracked by Wall St. Rank hold JAZZ as of Q1 2018.

  • Calton & Associates reported no remaining Jazz Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Calton & Associates sold 390 Jazz Pharmaceuticals shares in Q1 2018, an estimated $59K.
  • Calton & Associates first reported a position in Jazz Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Calton & Associates's Jazz Pharmaceuticals position peaked at $59K in Q4 2017.
  • 323 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2018.

Based on Calton & Associates's 13F filing for Q1 2018, filed 17 Apr 2018.